Oritavancin: An investigational lipoglycopeptide antibiotic

American Journal of Health-System Pharmacy

Volumn 70, Issue 1, 2013, Pages 23-33

  Karaoui, Lamis R ^a   El Lababidi, Rania ^b   Chahine, Elias B ^c  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b FLORIDA HOSPITAL   (United States)

^c PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; ORITAVANCIN; VANCOMYCIN;

BACTEREMIA; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRY SKIN; EAR DISEASE; ENDOCARDITIS; EYE DISEASE; FEVER; HEADACHE; HUMAN; HYPOTENSION; MACROPHAGE; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAIL DISEASE; NAUSEA; NONHUMAN; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; PLASMA HALF LIFE; PRIORITY JOURNAL; RECTUM DISEASE; REVIEW; RHINITIS; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84872303125     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110572     Document Type: Review

References (65)

1. Daemmrich AA. Targanta Therapeutics: hitting a moving target. Harvard Business School 2009; case 709-002.
2. Ward KE, Mersfelder TL, La Plante KL. Oritavancin - an investigational glycopeptide antibiotic. Expert Opin Investig Drugs. 2006; 15:417-29.
3. Bouza E, Burillo A. Oritavancin: a novel lipoglycopeptide active against grampositive pathogens including multiresistant strains. Int J Antimicrob Agents. 2010; 36:401-7.
4. Townsend ML, Wilson D, Pound M et al. Emerging treatment options for complicated skin and skin structure infections: oritavancin. Clin Med Insights Ther. 2010; 2:25-35.
5. Zhanel GG, Calic D, Schweizer F et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010; 70:859-86. [Erratum, Drugs. 2011; 71:526.]
6. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 2003; 26:511-32. (Pubitemid 36187412)
7. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010; 30:80-94.
8. Guay DR. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy. 2004; 24:58-68. (Pubitemid 38056252)
9. Patti GJ, Kim SJ, Yu TY et al. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J Mol Biol. 2009; 392:1178-91.
10. Kim SJ, Cegelski L, Stueber D et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008; 377:281-93.
11. Arhin FF, Draghi DC, Pillar CM et al. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother. 2009; 53:4762-71.
12. Streit JM, Fritsche TR, Sader HS et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004; 48:137-43. (Pubitemid 38221510)
13. Mendes RE, Moet GJ, Janechek MJ et al. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010; 54:2704-6.
14. Putnam SD, Sader HS, Moet GJ et al. Worldwide summary of telavancin spectrum and potency against gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis. 2010; 67:359-68.
15. Vashisht R, Weshnoweski B, Tailor F et al. Activity of oritavancin against S. aureus, S. epidermidis, Enterococcus spp. and S. pneumoniae, isolated from Canadian hospitals: results of the CANWARD 2007. Paper presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Annual Meeting. Washington, DC; 2008 Oct.
16. Arhin FF, Sarmiento I, Belley A et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008; 52:1597-603. (Pubitemid 351614648)
17. Arhin FF, Sarmiento I, Parr TR Jr. Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother. 2009; 64:868-70.
18. O'Connor R, Baines SD, Freeman J et al. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J Antimicrob Chemother. 2008; 62:762-5.
19. Citron DM, Kwok YY, Appleman MD. In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic gram-positive cocci. Anaerobe. 2005; 11:93-5. (Pubitemid 40381184)
20. Heine HS, Bassett J, Miller L et al. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother. 2008; 52:3350-7.
21. Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006; 50:841-51. (Pubitemid 43327786)
22. Seral C, van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003; 47:2283-92. (Pubitemid 36753584)
23. Rupp ME, Fey PD, Longo GM. Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother. 2001; 47:705-7. (Pubitemid 32447666)
24. Kaatz GW, Seo SM, Aeschlimann JR et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998; 42:981-3. (Pubitemid 28216399)
25. Gerber J, Smirnov A, Wellmer A et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother. 2001; 45:2169-72. (Pubitemid 32591722)
26. Sahm DF, Blosser RS, Loutit JS et al. Selection studies for oritavancin-resistant Staphylococcus aureus and enterococci. Abstract presented at 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: 2003 Sep.
27. Noviello S, Ianniello F, Esposito S. In vitro activity of LY333328 (oritavancin) against gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci. J Antimicrob Chemother. 2001; 48:283-6. (Pubitemid 32755293)
28. Baltch AL, Smith RP, Ritz WJ et al. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1998; 42:2564-8. (Pubitemid 28462894)
29. Zelenitsky SA, Booker B, Laing N et al. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1999; 43:592-7. (Pubitemid 29109524)
30. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother. 2008; 62:1078-85.
31. Belley A, Grenon-Neesham, Arhin F et al. Assessment by time-kill methodology of the synergistic effect of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 2008; 52:3820-2.
32. Nguyen HA, Denis O, Vergison A et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by Staphylococcus aureus small-colony variant strains isolated from a cystic fibrosis patient: study of antibiotic combinations. Antimicrob Agents Chemother. 2009; 53:1443-9.
33. Rubino CM, van Wart SA, Bhavnani SM et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009; 53:4422-8.
34. Bhavnani SM, Owen JS, Loutit JS et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004; 50:95-102. (Pubitemid 39335843)
35. Rowe PA, Brown TJ. Protein binding of 14C-oritavancin. Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2001 Dec.
36. McKay GA, Beaulieu S, Sarmiento I et al. Impact of human serum albumin on oritavancin in vitro activity against enterococci. Antimicrob Agents Chemother. 2009; 53:2687-9.
37. Arhin FF, McKay GA, Beaulieu S et al. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus. Diagn Microbiol Infect Dis. 2009; 65:207-10.
38. Fetterly GJ, Ong CM, Bhavnani SM et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005; 49:148-52. (Pubitemid 40065786)
39. Bhavnani SM, Passarell JA, Owen JS et al. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006; 50:994-1000. (Pubitemid 43327805)
40. Boylan CJ, Campanale K, Iversen PW et al. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003; 47:1700-6. (Pubitemid 36548557)
41. McKay GA, Beaulieu S, Arhin FF et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium. J Antimicrob Chemother. 2009; 63:1191-9.
42. Coyle EA, Rybak MJ. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2001; 45:706-9. (Pubitemid 32182012)
43. Arhin FF, McKay GA, Beaulieu S et al. Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes. Int J Antimicrob Agents. 2009; 34:550-4.
44. Lemaire S, Kosowska-Shick K, Julian K et al. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin Microbiol Infect. 2008; 14:766-77.
45. Mercier RC, Stumpo C, Rybak MJ. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother. 2002; 50:19-24. (Pubitemid 34785250)
46. Zhanel GG, Kirkpatrick ID, Hoban DJ et al. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1998; 42:2427-30. (Pubitemid 28420391)
47. Mercier RC, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother. 1997; 41:1307-12. (Pubitemid 27231432)
48. De la Pena A, Chien J, Geiser J et al. Microbiological outcomes and pharmacokinetics of oritavancin in patients with gram-positive bacteremia. Paper presented at 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy; 2002 Apr.
49. Loutit J, O'Riordan W, San Juan J et al. Phase 2 trial comparing four regimens of oritavancin in the treatment of patients with Staphylococcus aureus bacteremia. Paper presented at 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic; 2004 May.
50. Dunbar LM, Milata J, Fitzpatrick M et al. Efficacy of oritavancin at single or infrequent doses for the treatment of complicated skin and skin-structure infections. Paper presented at 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland; 2009 May.
51. Dunbar LM, Milata J, McClure T et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011; 55:3476-84.
52. Wasilewski M, Disch D, Mcgill J et al. Equivalence of shorter course therapy with oritavancin compared to vancomycin/cephalexin in complicated skin/skin structure infections. Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2001 Dec.
53. Giamarellou H, O'Riordan W, Harris H et al. Phase III trial comparing 3-7 days of oritavancin versus 10-14 days of vancomycin/cephalexin in the treatment of patients with skin/skin structure infections (cSSSI). Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2003 Sep.
54. Hartman CS, Bates BM, Wasilewski MM. Oritavancin in the treatment of complicated skin and skin structure infections: combined results of two phase 3 multinational trials. Paper presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Infectious Diseases Society of America (IDSA) Meeting. Washington, DC; 2008 Oct.
55. ClinicalTrials.gov. Oritavancin versus IV vancomycin for the treatment of patients with acute bacterial skin and skin structure infection (SOLO I). http://clinicaltrials.gov/ct2/show/NCT01252719?term=oritavancin&rank=1 (accessed 2011 Aug 27).
56. ClinicalTrials.gov. Oritavancin versus IV vancomycin for the treatment of patients with acute bacterial skin and skin structure infection (SOLO II). http://clinicaltrials.gov/ct2/show/NCT01252732?term=oritavancin&rank=2 (accessed 2011 Aug 27).
57. Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment (draft guidance. August 2010). www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf (accessed 2011 Aug 31).
58. Targanta Therapeutics Corporation. Targanta announces launch of oral oritavancin development program against C. difficile bacterial infection. http://media.integratir.com/targ/PressReleases/ TARG%20C%20Diff%20Program%20042108.pdf (accessed 2011 Aug 31).
59. Van Bambeke F, Saffran J, Mingeot- Leclercq MP et al. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother. 2005; 49:1695-700.60.
60. Moriarty SR, Wasilewski MM, Rosen AS et al. Safety of oritavancin versus vancomycin for treatment of patients with complicated skin and skin structure infections. Paper presented at 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland; 2009 May.
61. Darpo B, Lee SK, Moon TE et al. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study. J Clin Pharmacol. 2010; 50:895-903.
62. Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2010; 67:1640-4.
63. Targanta Therapeutics Corporation. Briefing document for the anti-infective drugs advisory committee, November 19, NUVOCID (oritavancin diphosphate for injection) for treatment of complicated skin and skin structure infections. NDA 22-153. www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-04- Targanta.pdf (accessed 2011 Aug 31).
64. Belley A, Neesham-Grenon E, McKay G et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009; 53:918-25.
65. Liu S, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52:e13-55.